Cynata Therapeutics is a clinical‐stage biotechnology company specializing in the development of cell therapies using its proprietary Cymerus™ platform. The Cymerus process leverages induced pluripotent stem cells (iPSCs) to generate mesenchymal stem cells (MSCs) on a large scale, aiming to overcome the variability and supply challenges associated with donor‐derived MSCs. By utilizing a single, well‐characterized iPSC master cell bank, the company seeks to deliver consistent, off‐the‐shelf cell therapies for a range of inflammatory and degenerative conditions.
The company’s lead product candidate, CYP-001, is an iPSC‐derived MSC therapy being evaluated in a Phase 1 clinical trial for the prevention and treatment of acute graft‐versus‐host disease in patients undergoing hematopoietic stem cell transplantation. In parallel, Cynata is advancing preclinical and early clinical studies of CYP-004, an intra‐articular MSC therapy for the treatment of knee osteoarthritis. These programs are designed to demonstrate both safety and efficacy in conditions with significant unmet medical needs.
Founded in 2015 and headquartered in Melbourne, Australia, Cynata holds exclusive global rights to the Cymerus technology, which was originally developed through collaboration between Kyoto University and other research institutions. The company’s operations extend to the United Kingdom, where it conducts clinical development activities, and it maintains regulatory and manufacturing partnerships in key markets, including the United States and Japan.
Cynata’s management team combines experience in cell therapy development, regulatory affairs and commercialization strategy. The company has also established collaborations with major industry partners to support late‐stage development and potential commercialization. Through its innovative platform and strategic alliances, Cynata Therapeutics aims to bring standardized, scalable cell therapies to patients worldwide.
AI Generated. May Contain Errors.
